The COVID-19 pandemic has made us realize the need for transformation in the health system, including resilience in dealing with emergencies, especially health. The government realizes that one of the vital policies in transforming the health system is through the resilience of the domestic health industry.

Learning from this, Indonesia rose and recovered by transforming the health system, "especially those related to medicines, vaccines and medical devices needed by the community, which can be produced domestically," said the Minister of Health when opening

The Minister of Health added that the transformation of health resilience has been pursued since 2021 and has produced proud results. One of them is that the number of domestic vaccine manufacturers capable of producing vaccines has increased from one to

"We have one vaccine company called bio farma, in the last three years Indonesia has increased the number of vaccine companies from one and has increased to three until this year," said the Minister of Health.

In line with this success, the Minister of Health also mentioned that vaccine manufacturing technology is also advancing, Indonesia has been able to produce four types of vaccines, namely virus-based, mRNA, recombinant protein and viral vector.

"There are four vaccine manufacturing technologies in the world, the ancient ones are virus and protein-based vaccines, but there are also modern vaccines based on vectors and mRNA, Indonesia, which previously could only produce two, can now be produced domestically," said the Minister of Health.

Currently, our domestic vaccine industry can also produce 9 out of 14 routine immunization antigens, namely BCG vaccine, Diphtheria, Pertussis, Tetanus, Hepatitis, Influenza (HIB), Oral Polio (OPV), Inactivated Polio Vaccine (IPV) and Human Papillomavirus Vaccine (HPV).

Further success, said the Minister of Health, imports of drug raw materials began to decrease, "eight of the ten most widely used drug raw materials can already be produced domestically. Some of the raw materials include Paracetamol, Clopidogrel and Atorvastatin," said the Minister of Health.

Technological advances also lead to more sophisticated treatment. Indonesia realizes this by producing domestic biological products including Erythropoietin alpha, Insulin glargine, Rituximab, Enoxaparin, Insulin aspart, and HyFC EPO.

"The realization of domestic medical device spending has also been reported to have increased in recent times. Even within a period of 6 months, from January to June 2023, the Ministry of Health was recorded to have realized around Rp 9 trillion of the domestic medical device expenditure budget," added the Minister of Health.

It was also reported that 17 out of 19 medical devices with the highest spending and usage in healthcare facilities (top value & volume) include Continuous ventilator, Patient monitor / Cardiac monitor, Endoscope and accessories and Mobile x-ray.

And 10 other in vitro diagnostic medical devices including COVID-19 Antigen RDT, Hepatitis B, Tuberculosis, Hepatitis A, Hepatitis C, Malaria, Dengue, and HIV.

Another success in the field of phytopharmacology, we are currently able to produce 6 phytopharmaceutical products, including capsules of a combination of celery herb extracts and cat whisker leaves (Tensigard Capsules), capsules of mixed extracts of bungur leaves and cinnamon bark (Diabetadex Capsules).

With this achievement, the Minister of Health wants it to be a foothold for Indonesia to make another big leap in the health sector towards a healthy and advanced Indonesia in 2045.

This achievement will not be realized without the cooperation and collaboration of various parties. Therefore, at the 59th HKN commemoration, awards were given as a form of appreciation to institutions or companies, stake holders and health personnel who have played an active role and contributed to achieving health transformation, especially health resilience.

"Hopefully this award can increase the enthusiasm to work more professionally in supporting resilience, especially in the field of pharmaceuticals and medical devices," said the Director General of Pharmaceuticals and Medical Devices, L. Rizka Andalusia.